News | November 12, 2021
Covaxin well tolerated with no safety concerns: Lancet
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
The company expects to begin shipping this product before the end of its fiscal first quarter, ending December 31, 2021
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
Ind-Ra continues to expect IPM’s revenue to grow over 12% yoy in FY22
Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021
The new facility will provide an important boost to vaccine capacity in Africa
It is the world’s first DNA-based Covid vaccine
Trivector Biomed has been promoting its Novaerus air disinfection solution across hospitals and health care facilities across India.
This is the eighth Covid-19 vaccine to receive Emergency Use Listing
Sputnik Light has been authorised in more than 15 countries with the registration process ongoing in a further 30 countries
Subscribe To Our Newsletter & Stay Updated
